Literature DB >> 8075903

Psychiatric symptoms in cannabis users.

H Thomas1.   

Abstract

The usual phenomena of cannabis intoxication include experiences which in a non-intoxicated state would be considered as psychiatric symptoms. These can be distinguished from adverse reactions to cannabis, the commonest of which is an acute anxiety state. Acute psychotic episodes can also follow ingestion of the drug but are infrequent. These can be classified as acute confusional states and episodes occurring in clear consciousness. Neither presentation consistently shows enough specific features to warrant the diagnosis of 'cannabis psychosis' as a distinct clinical entity. The evidence that cannabis has a causative role in chronic psychotic or affective disorders is not convincing, although the drug may modify the course of an already established illness. Further controlled studies would be required to clarify the aetiological significance of the drug in these conditions.

Entities:  

Mesh:

Year:  1993        PMID: 8075903     DOI: 10.1192/bjp.163.2.141

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  24 in total

1.  Case report: adverse effects of taking tricyclic antidepressants and smoking marijuana.

Authors:  V Mannion
Journal:  Can Fam Physician       Date:  1999-11       Impact factor: 3.275

2.  Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.

Authors:  Stanley Zammit; Peter Allebeck; Sven Andreasson; Ingvar Lundberg; Glyn Lewis
Journal:  BMJ       Date:  2002-11-23

3.  Gene-environment interplay in affect and dementia: emotional modulation of cognitive expression in personal outcomes.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

4.  Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats.

Authors:  Erin M Rock; Cheryl L Limebeer; Gavin N Petrie; Lauren A Williams; Raphael Mechoulam; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2017-04-20       Impact factor: 4.530

5.  Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice.

Authors:  A Zimmer; E Valjent; M Konig; A M Zimmer; P Robledo; H Hahn; O Valverde; R Maldonado
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

6.  D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration.

Authors:  F Nava; G Carta; A M Battasi; G L Gessa
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

7.  Marijuana use and breastfeeding.

Authors:  Josephine Djulus; Myla Moretti; Gideon Koren
Journal:  Can Fam Physician       Date:  2005-03       Impact factor: 3.275

Review 8.  Amygdala FAAH and anandamide: mediating protection and recovery from stress.

Authors:  Ozge Gunduz-Cinar; Matthew N Hill; Bruce S McEwen; Andrew Holmes
Journal:  Trends Pharmacol Sci       Date:  2013-10-25       Impact factor: 14.819

Review 9.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

10.  Candyflipping and Other Combinations: Identifying Drug-Drug Combinations from an Online Forum.

Authors:  Michael Chary; David Yi; Alex F Manini
Journal:  Front Psychiatry       Date:  2018-04-30       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.